AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6907170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31996580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal repair
Number of subjects: 64
Study 31996580 — intervention group
Group type: COMPARATOR
Intervention: Transperineal repair
Number of subjects: 64
Study 31611496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic solution, pH 1-2 (CS)
Number of subjects: 135
Study 31611496 — intervention group
Group type: COMPARATOR
Intervention: Distilled water, pH 6.9 (DW)
Number of subjects: 135
Study 31611496 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline solution, pH 10-11 (KS)
Number of subjects: 135
Study 28597306 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept-methotrexate combination therapy
Number of subjects: 0
Study 28597306 — intervention group
Group type: COMPARATOR
Intervention: Placebo-methotrexate combination therapy
Number of subjects: 0
Study 25123447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 20
Study 25123447 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 20
Study 23816488 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention consisting of 3-4 short MI sessions and a maintenance phase delivered by trained researchers.
Number of subjects: 0
Study 23816488 — intervention group
Group type: COMPARATOR
Intervention: Routine advice (Control group)
Number of subjects: 0
Study 21424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (prednisolone 0.5%)
Number of subjects: 117
Study 21424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricants
Number of subjects: 117
Study 21424238 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drops
Number of subjects: 117
Study 21424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment duration
Number of subjects: 117
Study 21424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 117
Study 19894007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed signal therapy
Number of subjects: 95
Study 19894007 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 95
Study 17362810 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 7 days
Number of subjects: 575
Study 17362810 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days
Number of subjects: 575
Study 15279531 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 204
Study 15279531 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial Rehabilitation (PSR)
Number of subjects: 204
Study 15279531 — intervention group
Group type: COMPARATOR
Intervention: Standard Services
Number of subjects: 204
Study 11210396 — intervention group
Group type: COMPARATOR
Intervention: NN703 (growth hormone secretagogue) administered po as a solution, dose levels: 8, with 6 subjects on active treatment per dose level.
Number of subjects: 48
Study 11210396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), 2 subjects per dose level.
Number of subjects: 48
Study 9553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etretinate therapy
Number of subjects: 15
Study 9553909 — intervention group
Group type: COMPARATOR
Intervention: Normal skin from RTRs
Number of subjects: 15
Study 9553909 — intervention group
Group type: COMPARATOR
Intervention: SCCs, BCCs, dysplastic lesions, and viral warts
Number of subjects: 15
Study 7715058 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 1323
Study 7715058 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercise
Number of subjects: 1323
Study 7715058 — intervention group
Group type: COMPARATOR
Intervention: No exercise component
Number of subjects: 1323
Study 2667615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 18
Study 2667615 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 18
Study 359938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 99
Study 359938 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 99
Study 31834814 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily running exercise for 7 days
Number of subjects: 9
Study 31379058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir or adefovir treatment for 4 years
Number of subjects: 25
Study 31379058 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HBsAg clearance profiles (CPs)
Number of subjects: 25
Study 27851857 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline, 1.0 mg/kg every 12 hours for a minimum of four 24-hour dosing cycles
Number of subjects: 541
Study 27851857 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem, 1.0 g every 24 hours for a minimum of four 24-hour dosing cycles
Number of subjects: 541
Study 27851857 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 541
Study 27851857 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 541
Study 25611803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone (400 μg)
Number of subjects: 15
Study 25611803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25611803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone (400 μg) administered 30 min before albuterol
Number of subjects: 15
Study 25611803 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 30 min before albuterol
Number of subjects: 15
Study 25739188 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol (intravenous drip, 400 ml per day, 10 days)
Number of subjects: 90
Study 25739188 — intervention group
Group type: COMPARATOR
Intervention: Essentiale N (intravenous bolus, 5 ml per day, 10 days)
Number of subjects: 90
Study 22621970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of 1,25(OH)(2)D
Number of subjects: 1099
Study 22621970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tertiles of 1,25(OH)(2)D after adjustment for FGF-23
Number of subjects: 1099
Study 22621970 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 1099
Study 19533757 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PDT (combined type I photorejuvenation with wrinkle reduction)
Number of subjects: 37
Study 19533757 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 37
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg etanercept intradiscally
Number of subjects: 36
Study 17585221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15334011 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 60
Study 15334011 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 60
Study 15334011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 60
Study 11142672 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 24
Study 11142672 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste (non‐triclosan, conventional fluoride toothpaste)
Number of subjects: 24
Study 9704955 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme (up to 6 U, 300 g)
Number of subjects: 44
Study 9704955 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic red blood cells (RBCs)
Number of subjects: 44
Study 9704955 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 44
Study 8003843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-impact exercise (test group)
Number of subjects: 27
Study 8003843 — intervention group
Group type: COMPARATOR
Intervention: Low-impact exercise (control group)
Number of subjects: 27
Study 2805891 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who played with both cans and tubes in their home for 1 month
Number of subjects: 50
Study 2805891 — intervention group
Group type: COMPARATOR
Intervention: 14-month-olds (untrained)
Number of subjects: 50
Study 2805891 — intervention group
Group type: COMPARATOR
Intervention: 20-month-olds (untrained)
Number of subjects: 50
Study 30408227 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative group received 30 pairings of a peripheral electrical nerve stimulus (ES) during the most active phase of the motor cortex
Number of subjects: 24
Study 30408227 — intervention group
Group type: COMPARATOR
Intervention: Control group received low intensity ES that did not stimulate the nerve
Number of subjects: 24
Study 30408227 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative group
Number of subjects: 24
Study 28449721 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP‐patient interview.
Number of subjects: 400
Study 28449721 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 400
Study 28449721 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention based on the implementation of the Ariadne principles.
Number of subjects: 400
Study 25738481 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI-based treatment (enalapril)
Number of subjects: 6083
Study 25738481 — intervention group
Group type: COMPARATOR
Intervention: Diuretic-based treatment (hydrochlorothiazide)
Number of subjects: 6083
Study 23175450 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 21198801 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the needle prior to administering diclofenac sodium intramuscularly
Number of subjects: 100
Study 21198801 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique (not changing the needle)
Number of subjects: 100
Study 18364323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free formula with 10(9)CFU B. lactis Bb12 and 5x10(8)CFU St. thermophilus TH4 per gram of powder
Number of subjects: 224
Study 18364323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free formula with 10(8)CFU B. lactis Bb12 and 5x10(7)CFU St. thermophilus TH4 per gram of powder
Number of subjects: 224
Study 18364323 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free formula (Control)
Number of subjects: 224
Study 16433809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% in thermophobic foam (CF) applied twice daily
Number of subjects: 26
Study 16433809 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily
Number of subjects: 26
Study 12769149 — intervention group
Group type: EXPERIMENTAL
Intervention: Menicon Z RGP contact lenses (tisilfocon A, Dk = 163) worn continuously for up to 30 days
Number of subjects: 60
Study 12769149 — intervention group
Group type: COMPARATOR
Intervention: ACUVUE hydrogel contact lenses (etafilcon A, Dk = 28) worn for up to 6 nights of extended wear
Number of subjects: 60
Study 10757587 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 10757587 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study 10757587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 10757587 — intervention group
Group type: COMPARATOR
Intervention: Desflurane and Sevoflurane
Number of subjects: 100
Study 9051539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-transdermal clonidine regimen (4 to 5 mu/kg oral clonidine and 0.2 mg/24 hours transdermal patch)
Number of subjects: 29
Study 9051539 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet and patch
Number of subjects: 29
Study 9051539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-transdermal clonidine regimen
Number of subjects: 29
Study 7786992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias-corrected estimation of model parameters
Number of subjects: 0
Study 7786992 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated envelope approach
Number of subjects: 0
Study 3354781 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 93
Study 3354781 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 93
Study 31587660 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) >158 mm Hg
Number of subjects: 485
Study 31587660 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) 158 mm Hg
Number of subjects: 485
Study 31587660 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) >158 mm Hg (adjusted analysis)
Number of subjects: 485
Study 29151562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep improvement program combined with aroma-necklace (marjoram and orange oil), 4 weeks, 1 hour per week
Number of subjects: 70
Study 29151562 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 70
Study 26447154 — intervention group
Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with nonfat milk (0.2 g fat)
Number of subjects: 20
Study 26447154 — intervention group
Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with reduced-fat milk (4.8 g fat)
Number of subjects: 20
Study 26447154 — intervention group
Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with whole milk (7.9 g fat)
Number of subjects: 20
Study 23233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pazopanib 0.5% for 3 weeks
Number of subjects: 20
Study 20054593 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA + EMD
Number of subjects: 56
Study 20054593 — intervention group
Group type: COMPARATOR
Intervention: DFDBA
Number of subjects: 56
Study 18448276 — intervention group
Group type: EXPERIMENTAL
Intervention: General movements (GMs) observation at term
Number of subjects: 175
Study 18448276 — intervention group
Group type: EXPERIMENTAL
Intervention: General movements (GMs) observation at three months
Number of subjects: 175
Study 18448276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly or definitely abnormal GMs at three months
Number of subjects: 175
Study 16496249 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 50
Study 16496249 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 50
Study 16496249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide + Timolol Fixed Combination (DTFC)
Number of subjects: 50
Study 16496249 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 50
Study 16496249 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 50
Study 14594782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosperm rye bread
Number of subjects: 19
Study 14594782 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rye bread
Number of subjects: 19
Study 14594782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber rye bread
Number of subjects: 19
Study 14594782 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (control)
Number of subjects: 19
Study 10699771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with meperidine as additional analgesia, self-administered by patients.
Number of subjects: 56
Study 10699771 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation with meperidine and midazolam administered by the anesthesiologist.
Number of subjects: 56
Study 9577115 — intervention group
Group type: COMPARATOR
Intervention: Blue-green equation testing with the IF-2 All-Color Anomaloscope
Number of subjects: 52
Study 8408793 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.1% ointment
Number of subjects: 20
Study 8408793 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate ointment
Number of subjects: 20
Study 2960897 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA (80 to 100 mg intravenously over three hours)
Number of subjects: 138
Study 2960897 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty (performed on the third hospital day)
Number of subjects: 138
Study 2960897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 2960897 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 138
Study 29906270 — intervention group
Group type: COMPARATOR
Intervention: Zirconia post
Number of subjects: 22
Study 29906270 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene fiber post
Number of subjects: 22
Study 26684775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the fornix
Number of subjects: 42
Study 26684775 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study 25602175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg bid
Number of subjects: 241
Study 25602175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid
Number of subjects: 241
Study 25602175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 750 mg bid
Number of subjects: 241
Study 25602175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 25602175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ranolazine 500 mg and 750 mg
Number of subjects: 241
Study 23969113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Number of subjects: 100
Study 23969113 — intervention group
Group type: COMPARATOR
Intervention: Absorbable hemostat
Number of subjects: 100
Study 23969113 — intervention group
Group type: COMPARATOR
Intervention: Fibrin Pad and Absorbable hemostat
Number of subjects: 100
Study 20001868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg/day
Number of subjects: 0
Study 20001868 — intervention group
Group type: COMPARATOR
Intervention: Intranasal buserelin acetate
Number of subjects: 0
Study 20001868 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone acetate 10 mg/day
Number of subjects: 0
Study 18360662 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 26
Study 18360662 — intervention group
Group type: COMPARATOR
Intervention: Regular maximum anchorage
Number of subjects: 26
Study 16893642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 42
Study 16893642 — intervention group
Group type: COMPARATOR
Intervention: Conventionally dosed chemotherapy (group A)
Number of subjects: 42
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Episcleral venous pressure in the supine position for older subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Episcleral venous pressure in the supine position for younger subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure in the supine position for older subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure in the supine position for younger subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in intraocular pressure in the supine position for younger subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in intraocular pressure in the supine position for older subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in episcleral venous pressure in younger subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in episcleral venous pressure in older subjects
Number of subjects: 2
Study 12897584 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure in older subjects
Number of subjects: 2
Study 10460994 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17-OHPc) at a dosage of 341 mg every 3 days
Number of subjects: 86
Study 10460994 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo every 3 days
Number of subjects: 86
Study 9569872 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified, all-metal, Extension Cone Paralleling (XCP-II) film holder
Number of subjects: 78
Study 9569872 — intervention group
Group type: COMPARATOR
Intervention: Conventional Extension Cone Paralleling (XCP-I) film holder
Number of subjects: 78
Study 1799476 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + VMCP
Number of subjects: 89
Study 1799476 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 89
Study 6349256 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 32
Study 6349256 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 32
Study 31957794 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach call plus invitation to engage in mental health tailored telephone counseling and assistance obtaining nicotine replacement therapy
Number of subjects: 982
Study 31957794 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 982
Study 31957794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 982
Study 31421395 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (136.6 mg aglycone equivalence)
Number of subjects: 99
Study 31421395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 27287858 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient THA (discharged on the same day)
Number of subjects: 220
Study 27287858 — intervention group
Group type: COMPARATOR
Intervention: Inpatient THA (discharged after an overnight stay)
Number of subjects: 220